Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.08 USD
Change Today +0.13 / 4.41%
Volume 127.7K
GALT On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
NASDAQ CM
As of 8:10 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

galectin therapeutics inc (GALT) Snapshot

Open
$2.96
Previous Close
$2.95
Day High
$3.15
Day Low
$2.92
52 Week High
07/25/14 - $16.55
52 Week Low
05/5/15 - $2.79
Market Cap
72.8M
Average Volume 10 Days
114.3K
EPS TTM
$-0.78
Shares Outstanding
23.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GALECTIN THERAPEUTICS INC (GALT)

galectin therapeutics inc (GALT) Related Bloomberg News

View More Bloomberg News

galectin therapeutics inc (GALT) Related Businessweek News

No Related Businessweek News Found

galectin therapeutics inc (GALT) Details

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company’s lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase 1/2 clinical trials in Belgium as a combination with a tumor vaccine in patients with advanced melanoma, a skin cancer. Galectin Therapeutics Inc., through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

7 Employees
Last Reported Date: 03/18/15
Founded in 2000

galectin therapeutics inc (GALT) Top Compensated Officers

Chief Executive Officer, President, Chief Med...
Total Annual Compensation: $698.4K
Executive Chairman and Executive Vice Preside...
Total Annual Compensation: $324.0K
Chief Financial Officer
Total Annual Compensation: $213.5K
Chief Operating Officer and Corporate Secreta...
Total Annual Compensation: $307.6K
Compensation as of Fiscal Year 2014.

galectin therapeutics inc (GALT) Key Developments

Galectin Therapeutics, Inc. Presents at Red Chip Global Online CEO Conference, Apr-23-2015 02:00 PM

Galectin Therapeutics, Inc. Presents at Red Chip Global Online CEO Conference, Apr-23-2015 02:00 PM. Speakers: James C. Czirr, Executive Chairman and Executive Vice President - Business Development.

Galectin Therapeutics, Inc. Presents at 2nd Annual Growth Capital Expo, Apr-13-2015

Galectin Therapeutics, Inc. Presents at 2nd Annual Growth Capital Expo, Apr-13-2015 . Venue: Caesars Palace, Las Vegas, Nevada, United States.

Galectin Therapeutics, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Galectin Therapeutics, Inc. reported consolidated earnings results for the year ended December 31, 2014. The company reported fiscal year 2014 net loss applicable to common stockholders of $17.0 million, or $0.78 loss per basic and diluted share, compared with the prior year's $21.9 million, or $.30 loss per basic and diluted share. The company attributed the decrease in net loss applicable to common stockholders is largely due to an $8.8 million or $0.53 per share one-time, non-cash charge related to the modification of certain warrants recorded second quarter 2013 and an unrelated one-time, non-cash stock compensation charge of $1.0 million or $0.06 per share recorded in third quarter 2013, which were partially offset by increased research and development expenses primarily related to its clinical program. Total operating loss was $15.4 million against $12.1 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GALT:US $3.08 USD +0.13

GALT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GALT.
View Industry Companies
 

Industry Analysis

GALT

Industry Average

Valuation GALT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALECTIN THERAPEUTICS INC, please visit www.galectintherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.